Rezlidhia Approved for Relapsed/Refractory AML With IDH1 Mutation
The FDA has approved Rezlidhia (olutasidenib) to treat patients with IDH1-mutated, relapsed or refractory acute myeloid leukemia.
Hematologic Cancers News
HEMATOLOGIC CANCER ADVISOR
Hematologic Cancers News
Clinical Challenge: Vomiting and Testicle Pain
A patient with a history of HIV presents to the ED with a 3- to 4-week history of vomiting and testicle pain. Can you make the diagnosis?
Consolidation Regimen Deemed “Highly Active” in Relapsed/Refractory Hodgkin Lymphoma
Consolidation with up to 8 cycles of brentuximab vedotin plus nivolumab appears active in high-risk, relapsed/refractory Hodgkin lymphoma.
Cancer-Related Mortality Tied to Residential Segregation
Residential racial and economic segregation across US counties is associated with higher cancer mortality, a study suggests.
Remote Assessment of Cognitive Function Feasible With Hematologic Malignancies
Researchers demonstrated the feasibility of remote cognitive assessments in patients with hematologic malignancies.
Ibrutinib Improves Survival vs Chemotherapy in CNS-Involved MCL
Patients with MCL and CNS involvement had superior survival when treated with ibrutinib rather than chemotherapy.
Breast Cancer Survivors Have Increased Risk of Implant-Associated ALCL
Breast cancer survivors have an increased risk of breast implant-associated ALCL, but the absolute risk is “extremely low,” according to researchers.
Adding Gilteritinib to Azacitidine Does Not Improve OS, EFS in Newly Diagnosed AML
Adding gilteritinib to azacitidine did not improve survival outcomes in patients with newly diagnosed, FLT3-mutated acute myeloid leukemia.
Significant Treatment Attrition Seen in Multiple Myeloma
Among patients who did not undergo autologous stem cell transplant, 52.7% advanced to second-line treatment.
Zanubrutinib May Produce Better Outcomes Than Ibrutinib in Rel/Ref CLL, SLL
Zanubrutinib may produce superior outcomes to ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Pediatric Cancer Survivors Experience Premature Aging
Young adult survivors of pediatric cancer experience significant premature aging, a retrospective study suggests.
Registry Data Quantify 5-Year Survival in Lower-Risk MDS
About 40% of patients with lower-risk myelodysplastic syndromes die of the disease within 5 years, a study suggests.
AEs Related to Antibody-Drug Conjugates Most Common in Breast Cancer
Researchers have characterized treatment-related adverse events associated with antibody-drug conjugates in clinical trials.
Epcoritamab Granted Priority Review for Relapsed/Refractory Large B-Cell Lymphoma
Epcoritamab is designed to bind to CD3 on T cells and CD20 on B cells, inducing T-cell-mediated killing of CD20+ cells.
FDA Approves Additional Dosing Schedule for Rylaze
The new dosing option was approved based on data from a phase 2/3 trial.
Atezolizumab Does Not Improve PFS in Previously Untreated Follicular Lymphoma
Adding atezolizumab to obinutuzumab and bendamustine does not improve progression-free survival and carries an increased risk of adverse events, a study suggests.
Consolidative Stem Cell Transplant May Improve Outcomes in PTCL
Researchers sought to determine whether patients with PTCL who have a complete response after A+CHP would benefit from SCT.
Lenalidomide Associated With Second Primary Malignancies in MM, Not Other Cancers
Lenalidomide increases the risk of developing a second primary malignancy in patients with multiple myeloma, a meta-analysis suggests.
Isatuximab Plus RVd Dubbed New Standard Care in Newly Diagnosed Multiple Myeloma
Adding isatuximab to RVd improves the rate of MRD negativity in patients with newly diagnosed, transplant-eligible multiple myeloma, a phase 3 trial suggests.
Atezolizumab Plus R-CHOP Deemed Unworthy of Additional Study in Diffuse Large B-Cell Lymphoma
Results of a phase 1/2 trial suggest the combination of atezolizumab and R-CHOP does not warrant further study in DLBCL, according to researchers.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Chronic Lymphocytic Leukemia
Loading... 
Loading...